Ogivri Injection, Powder, Lyophilized, For Solution
Product Images NDC 83257-003

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Ogivri (NDC 83257-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Biologics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 10 Ogivri For Injection 150 mg/vial Carton Label (Image 10)

Figure 10 Ogivri For Injection 150 mg/vial Carton Label (Image 10)
FDA Label Image

Figure 8 Ogivri For Injection 420 mgvial Carton Label With Diluent (Image 8)

Figure 8 Ogivri For Injection 420 mgvial Carton Label With Diluent (Image 8)
FDA Label Image

Figure 9 Ogivri For Injection 420 mg/vial Carton Label (Image 9)

Figure 9 Ogivri For Injection 420 mg/vial Carton Label (Image 9)
FDA Label Image

Figure 1 Studies 1 And 2: Cumulative Incidence Of Time To First Lvef (Image 01)

Figure 1 Studies 1 And 2: Cumulative Incidence Of Time To First Lvef (Image 01)
FDA Label Image

Figure 2 Study 3: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Image 02)

Figure 2 Study 3: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Image 02)
FDA Label Image

Figure 3 Study 4: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Image 03)

Figure 3 Study 4: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Image 03)
FDA Label Image

Figure 4 Duration Of Disease-free Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Image 04)

Figure 4 Duration Of Disease-free Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Image 04)
FDA Label Image

Figure 5 Duration Of Overall Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Image 05)

Figure 5 Duration Of Overall Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Image 05)
FDA Label Image

Figure 6 Duration Of Disease-free Survival In Patients With Adjuvant Treatment Of Breast Cancer (study 4) (Image 06)

Figure 6 Duration Of Disease-free Survival In Patients With Adjuvant Treatment Of Breast Cancer (study 4) (Image 06)
Figure 6 shows the duration of disease-free survival in patients with adjuvant treatment of breast cancer in Study 4. The graph displays different treatment combinations, including AC->T (doxorubicin + cyclophosphamide followed by docetaxel and trastuzumab), AC->TH (doxorubicin + cyclophosphamide followed by docetaxel, platinum salt, and trastuzumab), and TCH (docetaxel, platinum salt, and trastuzumab). The x-axis represents the number of years of disease-free survival, while the y-axis represents the number of patients. The Kaplan-Meier estimates are used to calculate the survival rates.*
FDA Label Image

Figure 7 Updated Overall Survival In Patients With Metastatic Gastric Cancer (study 7) (Image 07)

Figure 7 Updated Overall Survival In Patients With Metastatic Gastric Cancer (study 7) (Image 07)
Not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.